TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.

K L Jhaveri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.